Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. It has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. The company sells its products online. Abcam plc was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.
Abcam plc (ABCM) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2022 | 90.3 M | 134.9 M | 329.7 M | 1.06 B | 255.4 M |
| 2021 | 33.2 M | 134.6 M | 330 M | 986.1 M | 211.5 M |
| 2019 | 50.8 M | 46.9 M | 308.8 M | 811.4 M | 278.8 M |
| 2018 | 48.5 M | -87,100,000 | 61.9 M | 446.7 M | 171.8 M |
| 2017 | 39.3 M | -90,200,000 | 63.1 M | 414.8 M | 159.9 M |